Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, published Phase III results from the AFFIRM trial of enzalutamide (MDV3100) in metastatic castration-resistant prostate cancer patients previously treated with docetaxel-based chemotherapy in the New England Journal of Medicine

LONDON – A meta-analysis of cancer patients treated in Phase I studies of targeted drugs has confirmed that there is a much lower risk of the most serious side effects than with traditional chemotherapy

cancers Patient dosing has begun in a Phase I trial 7/13/12 Peregrine Pharmaceuticals Inc. (Tustin, Calif.) Bavituximab Monoclonal antibody Rectal adenocarcinoma The open-label Phase I trial began and will enroll up to 18 patients 7/17/12 Viral Genetics Inc. (San Marino, Calif.) HCQ Hydroxychlor-oquine Drug-resistant ovarian cancer First patient was enrolled in a Phase I trial 7/20/12 CENTRAL NERVOUS SYSTEM Acadia Pharmaceuticals Inc. (San Diego) AM-831 A small molecule that combines muscarinic

For retaspimycin, an inhibitor of heat-shock protein 90 (Hsp90), Infinity is enrolling for a Phase II trial in non-small-cell lung cancer in patients with a history of smoking

A July 2012 study completed by the Tufts Center for the Study of Drug Development (TCSDD) found that cancer patients in the U.S...It plans to examine potential new models designed to improve the efficiency and effectiveness of cancer prevention, early detection and treatment and maintain the quality of cancer care while reducing the financial burden of cancer for patients, health systems and society

The study showed T-cell responses against one or more of seven cancer-specific antigens in 61 percent (11/18) of evaluable cancer patients, and 89 percent (8/9) of patients with breast or ovarian cancer

A July 2012 study completed by the Tufts Center for the Study of Drug Development (TCSDD) found that cancer patients in the U.S...It plans to examine potential new models designed to improve the efficiency and effectiveness of cancer prevention, early detection and treatment and maintain the quality of cancer care while reducing the financial burden of cancer for patients, health systems and society

Diffusion Pharmaceuticals LLC, of Charlottesville, Va., said it completed the first cohort in a Phase I/II trial testing lead compound trans sodium crocetinate (TSC) in newly diagnosed primary brain cancer patients

GenSpera Inc., of San Antonio, Texas, said the FDA cleared the firm to start a Phase II trial of lead compound G-202 in prostate cancer patients who have failed prior hormonal therapy

One involves a Phase II trial of cabozantinib in non-small-cell lung cancer patients who have tested positive for gene fusions that activate RET, conducted by Naiyer Rizvi, a lung cancer specialist at Memorial Sloan Kettering Cancer Center

Beta Blockers Can Prevent Metastases Stress reduction in cancer patients has the reputation of being a touchy-feely approach...The authors concluded that treating breast cancer patients with either beta blockers or RANKL inhibitors such as Xgeva or Prolia (both denosumab, Amgen Inc.) could "inhibit both the early colonization of bone by metastatic breast cancer cells and the initiation of the 'vicious cycle' of bone destruction induced by these cells

The molecule, which gained European approval in 2009 for treating malignant ascites (abdominal fluid) in cancer patients, targets the T-cell antigen CD3 and epithelial cell adhesion molecule (EpCAM; CD326

The molecule, which gained European approval in 2009 for treating malignant ascites (abdominal fluid) in cancer patients, targets the T-cell antigen CD3 and Epithelial cell adhesion molecule (EpCAM; CD326

Sanofi SA, of Paris, informed the European Medicines Agency that it is withdrawing its application for marketing authorization for Mulsevo (semuloparin sodium) to prevent venous thromboembolism in certain cancer patients

In a trial of HER2-negative breast cancer patients, the drug led to median progression-free survival (PFS) of 8.3 months when administered in combination with capecitabine, vs. 7.5 months for those on capecitabine alone...The company previously reported that in pancreatic cancer patients the drug improved median overall survival to 12.5 months when administered in combination with gemcitabine, vs. 9.9 months for those on gemcitabine only

Sanofi SA, of Paris, informed the European Medicines Agency that it is withdrawing its application for marketing authorization for Mulsevo (semuloparin sodium) to prevent venous thromboembolism in certain cancer patients

In a trial of HER2-negative breast cancer patients, the drug led to median progression-free survival of 8.3 months when administered in combination with capecitabine, vs. 7.5 months for those on capecitabine alone...The company previously reported that in pancreatic cancer patients the drug improved median overall survival to 12.5 months when administered in combination with gemcitabine, vs. 9.9 months for those on gemcitabine only

Audeo found in a randomized Phase II trial of HA-Irinotecan (Camptosar, Pfizer Inc.) that progression-free survival was doubled in colon cancer patients receiving the HA-Irinotecan vs...The trial is being carried out at Monash Cancer Centre, Southern Health and Peninsula Oncology Centre in Melbourne, Australia and will enroll 40 first-line small-cell lung cancer patients

cancer patients, and 89% of those with breast or